LIVN logo

LIVANOVA PLC

LIVNNASDAQ
๐Ÿ† #1245 by market capEarnings Nov 4US Equity
$78.58โ–ฒ $2.16 (+2.75%)
๐ŸŒ… Pre-market$78.70โ–ฒ 0.15%Regular close ยท extended-hours price shown
1hโ€”
24hโ–ฒ 2.8%
7dโ–ฒ 0.6%
14dโ–ผ 3.4%
30dโ–ผ 5.3%
1yโ–ฒ 55.2%
๐ŸฆMarket Cap
$4.32B
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
+12.4%
Healthy
๐Ÿ“ŠGross Margin
68.1%
High
๐Ÿ’ตFCF Margin
10.1%
Healthy
โš–๏ธP/S Ratio
2.8x
Cheap
Otter Score
62
Fair

Trading Snapshot

Day Range
$78.23 โ€“ $79.49
52-Week Range
$48.57 โ€“ $85.76
Volume
$2.81B
Avg Volume
$1.90B
Shares Outstanding
54.9M
Next Earnings
Oct 2, 2026

Fundamentals Snapshot

Annual Revenue
$1.39B
Last Q Revenue
$391M
P/E Ratio
22.2
P/S Ratio
2.8x
EPS (TTM)
$3.38
Dividend Yield
โ€”

Why Investors Own LIVN

  • โœ“High-growth profile โ€” revenue up +17.7% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 51% gross margin and 18% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$1.39Bโ–ฒ +20.0% YoY
Gross Margin (TTM)
51.1%โ–ฒ +4.0% YoY
Operating Income (TTM)
$214Mโ–ฒ +20.0% YoY
Free Cash Flow (TTM)
$243Mโ–ฒ +20.0% YoY

About LIVANOVA PLC

LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.

๐Ÿฆฆ

Otter Score Breakdown

โ“˜
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Fair
62/100

Analyst Ratings

โ“˜
Consensus
Buy
16 analysts
Strong Buy6
Buy7
Hold3
Sell0
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates